Figure 3 Decreased AHI1 in human CD4+ T cells is associated with decreased proliferation and increased IFNγ production Decreased AHI1 in human CD4+ T cells.

Slides:



Advertisements
Similar presentations
Figure 3 Methodological strategy, flow cytometric analysis, cytokine profile, and clonality of brain-infiltrating cells Methodological strategy, flow cytometric.
Advertisements

Figure 3 Geometric mean titer ratio and seroprotection at week 4
Figure 1 Box plot of the venous diameter in lesions
Figure 5 Mononuclear cell subset isolation from spinal cord of mice with experimental autoimmune encephalomeylitis Mononuclear cell subset isolation from.
Figure 1 Stiff-person syndrome spectrum patient serum bound to membranes of live GlyRα1-transfected HEK293 cells Stiff-person syndrome spectrum patient.
Figure 2 Spinal cord lesions
Figure 3 B-cell amount and the frequency of various B-cell subtypes are differentially affected by FTY or DMF treatment B-cell amount and the frequency.
Figure Neuroimaging and pathology
Figure 3 Immunohistochemical analyses of positive and negative Epstein-Barr virus (EBV) control tissues using immunostaining Immunohistochemical analyses.
Figure 2 Disease progression slowed during each round of Treg infusions and correlated with increased Treg suppressive function Disease progression slowed.
Figure 2 Anti-LINGO-1 (Li81) does not affect cytokine production
Figure 4 Expression of type 1 IFN cytokines in different aDM subtypes
Figure 1 Treg percentage and suppressive function increased during each round of Treg infusions Treg percentage and suppressive function increased during.
Figure 2 The frequency of helper T cells (Th) within CD4+ population and TCRγδ within CD3+ cells is affected by FTY and DMF treatment The frequency of.
Figure 1 Effect of DMF therapy on T cell subsets
Figure 1 Linear relationship between CSF inflammation and glucose in meningitis; analysis stratified by diagnostic category (aseptic, n = 115 and microbial,
Figure 4 Abundance of cytokines which showed significant difference in expression in the plasma and the cultured PBMC of patients with RRMS Abundance of.
Figure 1 The abundance of CD3+ T cells and their subtypes are significantly affected by FTY and DMF treatment The abundance of CD3+ T cells and their subtypes.
Figure 3 Gene expression in CSF cell pellets
Figure 2 Correlation between total IgG levels and anti-AQP4 IgG titer
Figure Association of hippocampal subfield volumes to cognition by neopterin level, volumes, and cognition adjusted for age, education, race, sex, and.
Figure 2 Histopathologic findings of patients with both inflammatory myopathy and myasthenia gravis Histopathologic findings of patients with both inflammatory.
Figure 3 Temporal trends in FALS incidence
Figure 3 Receiver operating characteristics for CSF glucose (n = 225) and serum/CSF glucose ratio (n = 156) as predictors for microbial meningitis Receiver.
Figure 1 Characteristics of the German National MS Cohort
Figure 1 White matter lesion central vein visibility in MS and absence in small vessel disease (SVD)‏ White matter lesion central vein visibility in MS.
Figure 2 Mononuclear cell numbers after enzymatic dissociation methods in mice with clinical experimental autoimmune encephalomyelitis Mononuclear cell.
Figure 1 Schematic overview of flow cytometry Schematic overview on the analysis of peripheral immune cells by flow cytometry. Schematic overview of flow.
Figure Family tree with the HLA haplotyping of 6 members of the family
Figure 4 Relative abundances of the order Clostridiales and its family members are differentially changed by therapy Relative abundances of the order Clostridiales.
Figure Fundoscopic examination of the VZV-infected left eye over time
Table 2 Rs number, gene, OR, 95% CI, and permutation p value for the statistical significant variants resulted from allelic association analysis association.
Figure Alluvial plot of modified Rankin Scale (mRS) scores during and at the end of hospital stay Alluvial plot of modified Rankin Scale (mRS) scores during.
Figure 4 Leukocyte subset isolation from brain tissue by enzymatic dissociation Leukocyte subset isolation from brain tissue by enzymatic dissociation.
Figure 1 Phenotype and functional properties of B cells in MS and HCs at baseline Phenotype and functional properties of B cells in MS and HCs at baseline.
Figure 1 Responder rates of patients at 4 weeks compared with prevaccinated levels Responder rates of patients at 4 weeks compared with prevaccinated levels.
Figure 1 Proportions of the major B-cell subsets in DMF-treated patients Proportions of the major B-cell subsets in DMF-treated patients B cells were collected.
Figure 1 Anti-LINGO-1 (Li81) has no effect on activated T-cell proliferation Anti-LINGO-1 (Li81) has no effect on activated T-cell proliferation (A) Western.
Figure 6 Cellular composition after tissue dissociation
Figure 2 Immunohistological detection of EBV latent and early lytic proteins in MS and control brains Immunohistological detection of EBV latent and early.
Figure 2 CD4+ T-cell subsets fluorescence-activated cell sorting analysis in peripheral blood mononuclear cells of patients with multiple sclerosis treated.
Figure 1 CD52 expression on innate myeloid and lymphoid cell subsets
Figure 2 Changes in fatigue under treatment
Figure 2 Longitudinal relationship between CSF glucose and protein changes Longitudinal relationship between CSF glucose and protein changes Delta glucose.
Figure 1 Annualized percentage brain volume change
Figure 2 BVL according to on-study disability worsening
Figure 2 Repopulation of CD19+ cells in low and high BSA patients and calculation of the BSA Repopulation of CD19+ cells in low and high BSA patients and.
Figure 2 Frequency of the proportion of total WMLs with central veins in PPMS, RRMS, and SVD Frequency of the proportion of total WMLs with central veins.
Figure 1 Peripheral blood lymphocyte counts during dose titrationB-lymphocyte (CD19+; A) and total lymphocyte (CD45+; B) counts (cells/µL) in peripheral.
Figure 1 (A–D) Nuclear factor (erythroid-derived 2)-like 2–related transcripts are increased 6 weeks after treatment in responders but not in nonresponders.
Figure 2 C5B3 prevented AQP4-IgG–mediated CDC without affecting AQP4-IgG binding to AQP4 C5B3 prevented AQP4-IgG–mediated CDC without affecting AQP4-IgG.
Figure 3 DMF promotes an anti-inflammatory cytokine B-cell profile
Figure 1 bvFTD PINBPA network
Figure 2 Seizure outcomes
Figure 2 Overview of apheresis therapies
Yian Gu et al. Neurol Neuroimmunol Neuroinflamm 2019;6:e521
Ingo Kleiter et al. Neurol Neuroimmunol Neuroinflamm 2018;5:e504
Gitanjali Das et al. Neurol Neuroimmunol Neuroinflamm 2018;5:e453
Figure 1 Analysis of inflammatory cells in muscle biopsies
Figure 1 Tissue processing methods and cellular viability
Figure 3 C5B3 blocked MAC formation
Figure 3 Within-group comparisons (before–after)‏
Figure 1 Segmentation of the normal-appearing periependymal white matter Segmentation of the normal-appearing periependymal white matter The figure demonstrates.
Figure 5 C5B3 inhibited inflammatory infiltration in an NMOSD mouse model in vivo C5B3 inhibited inflammatory infiltration in an NMOSD mouse model in vivo.
Figure 2 Time from incident ADS event to MS diagnosis
Figure 2 Nonhuman primate brain immunohistochemistry
Figure 4 Venn diagram for B-cell Sup proteins compared with proteins from exosome-enriched fractions from a human B-cell line Venn diagram for B-cell Sup.
Figure 3 A receiver operating characteristic curve of days to IVMP as a predictor of failure to regain 0.2 logMAR (20/30) vision (AUC 0.84, p < 0.001)‏
Figure (A and B) Effect of canakinumab in muscle strength measured in each patient as mean bilateral GF (A) and TMS (B) during the mean study period of.
Figure 1 Glutamine antagonist JHU083 inhibits T-cell proliferation in vitro Glutamine antagonist JHU083 inhibits T-cell proliferation in vitro T-cell proliferation.
Presentation transcript:

Figure 3 Decreased AHI1 in human CD4+ T cells is associated with decreased proliferation and increased IFNγ production Decreased AHI1 in human CD4+ T cells is associated with decreased proliferation and increased IFNγ production (A) Naive CD4+ T cells were isolated from the peripheral blood of healthy subjects bearing risk (TT), protective (AA), or heterozygous (AT) alleles for rs4896153, and cells were activated with anti-CD3/CD28 followed by the analysis of cell proliferation by [3H]-thymidine incorporation 60 hours after stimulation. (B, C) A subset of these cells was further stimulated for 7 days, and IFNγ cytokine expression was measured by flow cytometry. (B) Frequency of CD4+IFNγ+ T cells bearing risk (TT) or protective (AA) alleles for the rs4896153 was analyzed by intracellular staining using flow cytometry. (C) Mean fluorescent intensity (MFI) of IFNγ expression from the activated T cells is shown. p Values were generated using Student's t test. Each dot represents an individual. Data are represented as mean ± SEM. IFNγ = interferon gamma. Belinda J. Kaskow et al. Neurol Neuroimmunol Neuroinflamm 2018;5:e414 Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology